다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Targeted oncology, v.9 no.4, 2014년, pp.349 - 357
Zhang, Minghui , Zhang, Xiaosan , Zhao, Shu , Wang, Yan , Di, Wenyu , Zhao, Gangling , Yang, Maopeng , Zhang, Qingyuan
AI-Helper
Triple-negative breast cancer (TNBC) is a particular type of breast cancer which is characterized by its biological aggressiveness, worse prognosis, and lack of prognostic markers or therapeutic targets in contrast with hormonal receptor-positive and human epidermal growth factor receptor 2-positive...
Cancer KR Bauer 109 9 1721 2007 10.1002/cncr.22618 Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and Her2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721-1728
Clin Oncol (R Coll Radiol) LS Kilburn 20 1 35 2008 10.1016/j.clon.2007.09.010 Kilburn LS, On Behalf of the TNT Trial Management Group (2008) Triple-negative breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 20(1):35-39
Nature CM Perou 406 747 2000 10.1038/35021093 Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747-752
Breast Cancer Res B Kreike 9 R65 2007 10.1186/bcr1771 Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65
Cancer TA Buchholz 104 676 2005 10.1002/cncr.21217 Buchholz TA, Tu X, Ang KK (2005) Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104:676-681
Breast Cancer Res Treat S Tsutsui 71 67 2002 10.1023/A:1013397232011 Tsutsui S, Ohno S, Murakami S (2002) Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71:67-75
Cancer Lett L O'Driscoll 201 225 2003 10.1016/S0304-3835(03)00518-4 O'Driscoll L, Linehan R, Kennedy SM et al (2003) Lack of prognostic significance of survivin, survivin-Delta Ex3, survivin-2B, galectin-3, bag-1, bax-alpha, and MRP-1 mRNAs in breast cancer. Cancer Lett 201:225-236
Clin Cancer Res K Tanaka 6 127 2000 Tanaka K, Iwamoto S, Gon G et al (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134
Clin Cancer Res JS Guillamo 15 3697 2009 10.1158/1078-0432.CCR-08-2042 Guillamo JS, Bouard S, Valable S et al (2009) Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res 15:3697-3704
Ann Oncol BM Ryan 17 597 2006 10.1093/annonc/mdj121 Ryan BM, Konecny GE, Kahlert S et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604
EMBO J CS Duckett 14 2685 1996 10.1002/j.1460-2075.1996.tb00629.x Duckett CS, Nava VE, Gedrich RW et al (1996) A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 14:2685-2694
J Cell Physiol F Li 208 476 2006 10.1002/jcp.20634 Li F, Ling X (2006) Survivin study: an update of “what is the next wave”? J Cell Physiol 208:476-486
Cancer Y Kajiwara 97 1077 2003 10.1002/cncr.11122 Kajiwara Y, Yamasaki F, Hama S et al (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077-1083
Histol Histopathol MH Andersen 17 669 2002 Andersen MH, Thor SP (2002) Survivin: a universal tumor antigen. Histol Histopathol 17:669-675
Cancer Res JE Korkola 63 7167 2003 Korkola JE, Devries S, Fridlyand J et al (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167-7175
Mod Pathol AC Fields 17 1378 2004 10.1038/modpathol.3800203 Fields AC, Cotsonis G, Sexton D et al (2004) Survivin expression in hepatocellualr carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 17:1378-1385
Br J Cancer G Ferrandina 92 271 2005 10.1038/sj.bjc.6602332 Ferrandina G, Legge F, Martinelli E et al (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92:271-277
Head Neck SF Preuss 30 1318 2008 10.1002/hed.20876 Preuss SF, Weinell A, Molitor M et al (2008) Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma. Head Neck 30:1318-1324
Clin Chem PN Span 50 1986 2004 10.1373/clinchem.2004.039149 Span PN, Sweep FC, Wiegerinck ET et al (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986-1993
Br J Cancer SM Kennedy 88 1077 2003 10.1038/sj.bjc.6600776 Kennedy SM, O'Driscoll L, Purcell R et al (2003) Prognostic importance of survivin in breast cancer. Br J Cancer 88:1077-1083
BMC Med DG Altman 10 51 2012 10.1186/1741-7015-10-51 Altman DG, McShane LM, Sauerbrei W et al (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10:51
Cancer G Guler 115 899 2009 10.1002/cncr.24103 Guler G, Huebner K, Himmetoglu C et al (2009) Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115:899-908
Br J Cancer L Lo muzio 89 2244 2003 10.1038/sj.bjc.6601402 Lo muzio L, Pannone G, Staibano S et al (2003) Survivin expression in oral squamous cell. Br J Cancer 89:2244-2248
.Virchows Arch. C Riva 447 695 2005 10.1007/s00428-005-0003-6 Riva C, Dainese E, Caprara G et al (2005) Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 447:695-700
Am J Clin Pathol SN Agoff 120 725 2003 10.1309/42F00D0DJD0J5EDT Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725-731
Clin Transl Oncol R Hitt 8 776 2006 10.1007/s12094-006-0131-8 Hitt R, Echarri MJ (2006) Molecular biology in head and neck cancer. Clin Transl Oncol 8:776-779
J Clin Neurosci M Kogiku 15 1198 2008 10.1016/j.jocn.2007.11.012 Kogiku M, Ohsawa I, Matsumoto K et al (2008) Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci 15:1198-1203
Radiat Oncol M Zimmermann 1 11 2006 10.1186/1748-717X-1-11 Zimmermann M, Zouhair A, Azria D et al (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1:11
Thyroid JA Knauf 21 11 1171 2011 10.1089/thy.2011.2111.ed Knauf JA (2011) Does the epidermal growth factor receptor play a role in the progression of thyroid cancer? Thyroid 21(11):1171-1174
Clin Cancer Res BA Schiff 10 8594 2004 10.1158/1078-0432.CCR-04-0690 Schiff BA, McMurphy AB, Jasser SA et al (2004) Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602
Ann Oncol V Ludovini 20 842 2009 10.1093/annonc/mdn727 Ludovini V, Bellezza G, Pistola L et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842-849
Ann Oncol JP Spano 16 102 2005 10.1093/annonc/mdi006 Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102-108
Clin Cancer Res X Wang 13 953 2007 10.1158/1078-0432.CCR-06-2167 Wang X, Zhang S, MacLennan GT et al (2007) Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 13:953-957
APMIS S Leibl 116 27 2008 10.1111/j.1600-0463.2008.00859.x Leibl S, Zigeuner R, Hutterer G et al (2008) EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 116:27-32
Clin Cancer Res NH Chow 7 1957 2001 Chow NH, Chan SH, Tzai TS et al (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957-1962
Mod Pathol S Stadlmann 19 607 2006 10.1038/modpathol.3800575 Stadlmann S, Gueth U, Reiser U et al (2006) Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 19:607-610
Cancer MF Rimawi 116 1234 2010 10.1002/cncr.24816 Rimawi MF, Shetty PB, Weiss HL et al (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116:1234-1242
Breast Cancer Res Treat R Dua 122 685 2010 10.1007/s10549-009-0592-x Dua R, Zhang J, Nhonthachit P et al (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122:685-697
N Engl J Med JA Bonner 354 567 2006 10.1056/NEJMoa053422 Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
J Biomed Biotechnol T Kosaka 2011 165214 2011 10.1155/2011/165214 Kosaka T, Yamaki E, Mogi A et al (2011) Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011:165214. doi: 10.1155/2011/165214
Int J Med Sci X Zhang 5 209 2008 10.7150/ijms.5.209 Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5:209-217
Trends Mol Med DC Altieri 7 542 2001 10.1016/S1471-4914(01)02243-2 Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547
Breast Cancer Res Treat PN Span 98 223 2006 10.1007/s10549-005-9153-0 Span PN, Tjan-Heijnen VC, Manders P et al (2006) High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223-230
Exp Mol Pathol Q Wang 79 100 2005 10.1016/j.yexmp.2005.05.002 Wang Q, Greene MI (2005) EGFR enhances survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 79:100-107
Br J Cancer D Xie 94 108 2006 10.1038/sj.bjc.6602904 Xie D, Zeng YX, Wang HJ et al (2006) Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer 94:108-114
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.